New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
08:36 EDTRIGLRigel still poised to report good fostamatinib results, says Stifel Nicolaus
After Rigel Pharmaceuticals reported that its fostamatinib drug for rheumatoid arthritis.had failed to demonstrate non-inferiority versus a competing drug, Stifel reports that the results don't alter its forecast for fostamatinib's Phae III trials. The firm thinks the decline in Rigel's stock following the results were overdone and it maintains a Buy rating.
News For RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
08:09 EDTRIGLJefferies views Rigel as rare biotech stock
Subscribe for More Information
May 19, 2015
12:30 EDTRIGLRigel Pharmaceuticals management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use